Semaglutide can yield weight loss, lower heart issues for at least four years in non-diabetic adults with overweight
Credit: Unsplash/CC0 Public Domain Two studies are being presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12-15 May), based on the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author group. The first new study, led by Professor Donna Ryan from Pennington Biomedical Research Center, New Orleans, U.S.,…